**Shorter leukocyte telomere length is associated with adverse COVID-19 outcomes: A cohort study in UK Biobank**

Qingning Wang, PhD,1,2, Veryan Codd, PhD,1,2, Zahra Raisi-Estabragh, MD,3,4, Crispin Musicha, PhD,11,2, Vasiliki Bountziouka, PhD,11,2, Stephen Kaptoge, PhD,15,6,7, Elias Allara,MD,5,6, Emanuele Di Angelantonio, MD,5,6,7,8, Adam S. Butterworth, PhD,5,6,7,8, Angela M. Wood, PhD,5,6,7,8,9,10, John R. Thompson, PhD,11, Steffen E, Petersen, MD,3,4, Nicholas C. Harvey, PhD,12,13, John N. Danesh, FMedSci,5,6,7,8,14, Nilesh J. Samani,FMedSci,1,2, Christopher P. Nelson, PhD1,2,†

1. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
2. NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
3. William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK;
4. Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, EC1A 7BE, London, UK
5. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
6. National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK.
7. British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge,UK.
8. Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
9. Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK
10. The Alan Turing Institute, London, UK
11. Department of Health Sciences, University of Leicester, UK
12. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK;
13. NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
14. Department of Human Genetics, Wellcome Sanger Institute, Hinxton, United Kingdom
* Corresponding author

**Corresponding author**

Christopher P. Nelson, chris.p.nelson@leicester.ac.uk, phone +44 (0)116 204 4745, address Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK

**Abstract** (word count=250)

**Background:** Older age is the most powerful risk factor for adverse coronavirus disease-19 (COVID-19) outcomes. It is uncertain whether leucocyte telomere length (LTL), previously proposed as a marker of biological age, is also associated with COVID-19 outcomes.

**Methods:** We associated LTL values obtained from participants recruited into UK Biobank (UKB) during 2006-2010 with adverse COVID-19 outcomes recorded by 30 November 2020, defined as a composite of any of the following: hospital admission, need for critical care, respiratory support, or mortality. Using information on 130 LTL-associated genetic variants, we conducted exploratory Mendelian randomisation (MR) analyses in UKB to evaluate whether observational associations might reflect cause-and-effect relationships.

**Findings:** Of 6,775 participants in UKB who tested positive for infection with SARS-CoV-2 in the community, there were 914 (13.5%) with adverse COVID-19 outcomes. The odds ratio (OR) for adverse COVID-19 outcomes was 1·17 (95% CI 1·05-1·30; P=0·004) per 1-SD shorter usual LTL, after adjustment for age, sex and ethnicity. Similar ORs were observed in analyses that: adjusted for additional risk factors; disaggregated the composite outcome and reduced the scope for selection or collider bias. In MR analyses, the OR for adverse COVID-19 outcomes was directionally concordant but non-significant.

**Interpretation:** Shorter LTL is associated with higher risk of adverse COVID-19 outcomes, independent of several major risk factors for COVID-19 including age. Further data are needed to determine whether this association reflects causality.

**Funding:** UK Medical Research Council, Biotechnology and Biological Sciences Research Council and British Heart Foundation.

**Research in context**

**Evidence before this study:**

We searched PubMed for articles with the terms “telomere length” and “COVID-19” to identify publications relating to telomere length and COVID-19 outcomes. We retained only research articles that used telomere length as a biomarker, identifying three articles. All of these studies showed a relationship between shorter telomere length and either COVID-19 severity or outcome. However, all had measured leucocyte telomere length (TL) after SARS-CoV-2 infection making it difficult to interpret whether shorter TL preceded infection or was due to higher white cell turnover in response to infection.

**Added value of this study:**

Our study is the largest study to date on the association of inter-individual variation in leucocyte telomere length with adverse outcomes from COVID-19 and the first to analyse telomere length that was measured prior to SARS-CoV-2 infection.

**Implications of all the available evidence**:

Our study suggests that independently of age, leucocyte telomere length is associated with greater risk of poor outcome from COVID-19, possibly through an effect on immune cell senescence, and that this explains some of the heterogeneity in inter-individual response to the infection.

**Introduction**

Older age has emerged as the most powerful risk factor for severe infection, requiring hospitalisation or critical care, and mortality from coronavirus disease 19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1,2  One potential mediator of this effect is ageing of the immune system, leading to increased levels of pro-inflammatorysenescent cells and reduced proliferative capacity of immune precursor cells.3,4 Telomere length (TL) is a key determinant of proliferative capacity and cellular lifespan, triggering senescence once a critically short TL is reached.5 TL − commonly measured in leucocytes (LTL) − shows a consistent negative association with age in cross sectional population cohorts and has previously been proposed as a marker of biological age for an individual. However, age only accounts for a small proportion of the substantial inter-individual variation in LTL6 that exists at all ages, including birth.7 More recently, TL has also been proposed as a marker of replicative capacity and repair ability8, both of which, within the haematopoietic system, could potentially impair an individual’s response to SARS-CoV-2 infection, above any effect of age.9,10

A few small case-control studies, in which LTL was measured after SARS-CoV-2 infection at the time of hospital admission, have reported associations of shorter LTL with hospitalisation and severe outcomes.11-13 However, their interpretation is complicated by the possibility that LTL measurements could have been influenced by white cell turnover in response to infection. To our knowledge, no study to date has reported on associations of prior (pre-infection) LTL values and adverse COVID-19 outcomes.

Here, we examine whether LTL measured several years prior to SARS-CoV-2 infection is associated with adverse COVID-19 outcomes, leveraging our recent completion of LTL measurements in 474,074 participants aged 40-69 at time of recruitment into UK Biobank (UKB)6 between 2006 and 2010.14, 15

**Methods**

*Participants:* Participants in UKB have been characterised in detail using questionnaires, physical measurements, urinary and plasma biomarker measurements, genomic assays and longitudinal linkage with multiple health record systems, including Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality data.16 We have described the associations of inter-individual variation in LTL with multiple biomedical traits and risk of several diseases in UKB.15 Since the onset of the COVID-19 pandemic, UKB has also linked participants with results from clinically indicated SARS-CoV-2 testing and COVID-19 outcomes. By linking participants in UKB to SARS-CoV-2 testing datasets of Public Health England (PHE),17 we identified participants who tested positive between 16 March 2020 and 30 November 2020; the latter date corresponds to the latest release of HES data to UKB. We used HES records to identify SARS-CoV-2 positive participants who were admitted to hospital due to COVID-19 (ICD-10 code ‘U07.1’) within 28 days after a positive SARS-CoV-2 test. We further extracted information on need for critical care admission and respiratory support, due to COVID-19 (ICD-10 code ‘U07.1’), via linkage to the ICNARC (Intensive Care National Audit and Research Centre) database, and deaths due to COVID-19 (ICD-10 code ‘U07.1’), from the Office for National Statistics (ONS) death registry data.

The UK Biobank has ethical approval from the North West Centre for Research Ethics Committee (Application 11/NW/0382), which covers the UK. UK Biobank obtained informed consent from all participants. Full details can be found at <https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics>. The generation and use of the data presented in this paper was approved by the UK Biobank access committee under UK Biobank application number 6077.

*LTL measurements*: Full details of the LTL measurements in UKB are provided elsewhere.6 Briefly, LTL was measured using an established PCR method that expresses LTL as a ratio (T/S ratio).6 LTL measurements were adjusted for technical variation, loge transformed and Z-standardised.6 In order to assess and adjust for within individual variability in LTL we measured LTL at two time-points (mean interval: 5·5 years) for 1,351 participants, yielding a regression-dilution ratio of ~0·68. Results in this study have been corrected for within-person variability of LTL values over time (abbreviated "usual LTL"), as described previously.6,15

*Outcome definitions:* Our study’s primary outcome was a composite of COVID-19-related outcomes (ICD-10 code ‘U07.1’): hospital admission, requirement for critical care, respiratory support, or mortality. We defined cases as those participants in UKB who tested positive for SARS-CoV-2 and had the primary outcome. For our primary outcome, controls were those who tested positive for SARS-CoV-2 but were not hospitalised within 28 days. To reduce the scope for collider bias18 we included only participants with positive SARS-CoV-2 tests done outside of hospital settings, since hospital admission itself may increase the likelihood of SARS-CoV-2 testing. The age, sex and ethnicity adjusted odds ratio (OR) for having a SARS-CoV-2 test (n=43,574) at any location, was 1·03, (95% CI 1·01-1·05; logistic regression P=1·0x10-4) per 1-SD shorter usual LTL.

We conducted several secondary analyses. First, we examined associations with each component of the primary composite endpoint. Second, we analysed the primary outcome using the rest of UKB participants as controls, as testing was unlikely to be random and the restriction to SARS-CoV-2 positive controls only is potentially subject to selection bias related to factors associated with infection.19 Third, to ensure that apparently post-COVID-19 outcomes were not re-admissions or influenced by proximate medical events prior to infection, we excluded participants with any hospital admission in the previous 6 months. Finally, we consider the impact of inflammation and baseline disease prevalence on LTL, to minimise the potential confounding from these factors on any LTL-COVID-19 outcomes relationship.

*Statistical analysis:* Univariable tests were performed using T-tests for continuous traits and Fishers exact or χ2 tests for categorical traits as appropriate. Analyses involved multivariable logistic regression, adjusting for age (at SARS-CoV-2 positive test), sex and ethnicity. Due to small numbers, ethnic groups other than White were combined and participants with missing ethnicity (n=14 cases and 46 controls) were excluded. To remove the correlation between LTL and age, we used the residuals of LTL adjusted for age at baseline within the statistical models. In specific models to estimate the impact on the association due to inflammation or disease prevalence we re-estimated LTL residuals adjusting for age at baseline and C-reactive protein or any of 123 curated diseases15 (**Supplementary Table**) respectively. ORs were further adjusted for baseline smoking status and body-mass index (BMI) recorded at entry into UKB. Results are described as ORs associated with the outcome per one standard deviation (SD) shorter LTL residual, with associated 95% confidence intervals (CI) and p-values.

In an exploratory analysis, we conducted one-sample Mendelian randomisation (MR) analyses in UKB20 to evaluate a causal relationship between shorter LTL and adverse COVID-19 outcomes, using the inverse-variance weighted (IVW)21 and weighted median22 methods with a set of 130 genome-wide significant (P<8.31x10-9), conditionally independent, uncorrelated and non-pleiotropic genetic variants we recently identified as genetic instruments for LTL.15 We used MR-Egger regression to assess robustness to horizontal pleiotropy.23

*Role of the funding body*: The Funders had no role in study design, data collection, data analyses, interpretation, or writing of this study.

**Results**

By 30 November 2020, 914 participants were identified with an adverse COVID-19 related outcome and 5861 participants were identified as primary controls (positive community test for COVID-19 but not hospitalised). Their characteristics are summarised in **Table 1**. On average, compared to controls, cases were older and more likely to be male and from a non-White background. At time of their entry into UKB, they also had a higher BMI and more likely to be current smokers. (**Table 1**).

LTL at entry to UKB was on average shorter in cases compared with controls (**Table 1**). The OR for the primary outcome was 1.17 (95% CI 1.05-1.30; logistic regression P=0·004) per 1-SD shorter usual LTL, after adjustment for age, sex and ethnicity (**Table 2**). The OR only slightly attenuated after further adjustment for smoking status and BMI (OR=1·15, 1·03-1·28), and after adjustment for the presence of any of 123 diseases recorded at baseline (OR=1·14, 1·02-1·26), while adjusting for CRP slightly increased the estimated effect size (OR=1·19, 1·06-1·33). As expected, older age, male sex and non-White ethnicity were each associated with higher risk of adverse COVID-19 outcomes independently of usual LTL (**Table 2**).

Sub-components of our study’s primary composite outcome were not mutually exclusive, as 46 cases contributed to all four sub-components (**Figure 1**). Shorter usual LTL was significantly associated with higher risk of each sub-component (**Table 2**). ORs were broadly similar to the main findings in analyses that replaced the SARS-CoV-2-positive control group with all UKB participants as controls or that excluded any participant with a hospital admission in the six months prior to testing positive for SARS-CoV-2 (**Table 2**).

In MR analyses, the IVW odds ratio was 1·30 (0·85-2·00; MR-IVW P=0·224) per 1-SD shorter genetically-determined LTL, a non-significant result directionally concordant with the observational finding (**Table 2**). Results were similar using the weighted median method (**Table 2**) and there was no evidence of horizontal pleiotropy (MR-Egger intercept P=0·591).

**Discussion**

In a study of 6,775 participants with a positive test for SARS-CoV-2 (nested within the 500,000-participant UKB), we have shown that individuals with shorter LTL assessed several years *prior* to SARS-CoV-2 infection had higher risk of adverse COVID-19 outcomes, even after adjustment for several established risk factors for COVID-19 including age. This finding suggests that shorter LTL is likely to be independently associated with COVID-19 hospitalisation and severity. The results of analysis of LTL-associated genetic variants and COVID-19 were directionally concordant with our observational findings but non-significant. Our results, therefore, encourage further investigation of the potential causal relevance of TL to adverse COVID-19 outcomes.

The validity of our results is supported by several observations. First, our study found associations between older age, male sex, and non-White ethnicity that have previously been linked with adverse COVID-19 outcomes in the UK.2 Each of these factors was associated much more strongly with COVID-19 outcomes than was shorter LTL. Second, we found significant associations of shorter LTL with each sub-component of our study’s primary composite outcome. Third, our main findings persisted after adjustment for multiple risk factors. Fourth, our overall result was robust to sensitivity analyses designed to minimise the scope for potential biases. For example, collider bias can lead to false associations between a risk factor and an outcome,18 as highlighted by studies related to understanding of COVID-19 disease risk and severity.19 Indeed, we found evidence for potential colliders in our own analysis, observing a small but significant association between shorter LTL and higher likelihood of SARS-CoV-2 testing. Hence, we only included participants with a positive SARS-CoV-2 test outside the hospital setting, as hospitalisation itself may increase the likelihood of testing. Finally, considering the potential impact of inflammageing on the observed result we further adjusted for C-reactive protein and found no meaningful changes in the association.

The biological mechanisms through which shorter LTL might increase risk of adverse outcomes from SARS-CoV-2 infection remain to be clarified. Our finding that the association was not substantially attenuated when we adjusted for the association of LTL with multiple diseases at baseline, suggest that, if this association is causal, it is probably not simply a reflection of co-morbidity due to the impact of shorter LTL on risk of these diseases. A potential mechanism relates to the impact of telomere length dynamics on aging of the immune system24 and the potential role of senescence in severe SARS-CoV-2 infection.3,4,25 While we have measured TL in leucocytes we believe these results likely reflects TL within T-cells in this scenario, although further studies would be required to confirm this. When challenged with infection, individuals with shorter LTL prior to infection would potentially have less proliferative capacity within the T-cell population required for an efficient response to SARS-CoV2, coupled with reduced lymphopoiesis following infection.9,26 Individuals with shorter LTL may also potentially already harbour a higher proportion of senescent T-cells, reducing the number of functional cells that are able to respond to infection.25 Additionally, senescent cells are known to adopt a pro-inflammatory phenotype, secreting high levels of cytokines, which can further drive inflammation in COVID-19 patients.25 Our results are also in concordance with previous studies showing that shorter LTL increases the risk of adverse outcome in other infections. 27,28

Our study has several limitations. UKB is not representative of the general UK population; only 6% of those invited to participate did so.29 The age distribution within UK Biobank includes participants aged 40-70 at baseline, who will be about 10-15 years older now, limiting the ability to assess association in individuals in other age groups. We were unable to fully assess ethnicity due to small numbers, though over time this limitation can be resolved with increased case numbers. Risk factor levels and mortality rates are lower than in the general population, although risk factor associations with mortality for a range of diseases are similar.30 Hence, further studies are warranted in other populations. Our one-sample Mendelian randomisation analysis in UKB had limited power to reliably estimate causal effects as fewer than one thousand participants had been hospitalised after a positive SARS-CoV-2 test and our genetic instrument of 130 variants, while using the most up to date information on LTL-associated variants, accounts for only ~4% of inter-individual variation in LTL.15 While there are data from large genetic studies of COVID-1931, they could not be used in our analysis because the outcome definitions differed substantially from those we used, and because of their inclusion of within hospital testing that is potentially a collider with LTL and COVID-19 outcomes. Larger sample sizes with comparable disease phenotypes should, therefore, enable more precise evaluation of a potential causal association between shorter LTL and adverse COVID-19 outcomes.

In conclusion, in the largest study to date, we provide evidence that shorter LTL is associated with higher risk of adverse COVID-19 outcomes, independent of several major risk factors for COVID-19.

**References**

1. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ* 2020; **369**: m1966

2. Williamson EJ, Walker AJ, Bhaskaran K, *et al.* Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; **584**:430–436.

3. De Biasi S, Meschiari M, Gibellini L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. *Nature Comms*. 2020; **11**: 3434.

4. Akbar AN & Gilroy DW. Aging immunity may exacerbate COVID-19. Science 2020; **369**: 256–257.

5. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. *PNAS* 1992; **89**: 10114–10118.

6. Codd V, Denniff M, Swinfield C, et al. A major population resource of 474,074 participants in UK Biobank to investigate determinants and biomedical consequences of leukocyte telomere length. *MedRxiv.* 2021; https://doi.org/10.1101/2021.03.18.21253457

7. Factor-Litvak P, et al. Leukocyte Telomere Length in Newborns: Implications for the Role of Telomeres in Human Disease. *Pediatrics*. 2016; **137**. pii: e20153927.

8. Aviv A, Shay JW. Reflections on telomere dynamics and ageing-related diseases in humans. *Philos Trans R Soc B*. 2018;**373**.20160436 DOI: 10.1098/rstb.2016.0436

9. Aviv A. Telomeres and COVID-19. *The FASEB Journal*. 2020; **34**: 7247– 7252.

10. Tsilingiris D, Tentolouris A, Eleftheriadou I, Tentolouris N. Telomere length, epidemiology and pathogenesis of severe COVID-19. Eur J Clin Invest. 2020; **50:**e13376.

11. Sanchez-Vazquez R, Guío-Carrión A, Zapatero-Gaviria A, Martínez P, Blasco MA. Shorter telomere lengths in patients with severe COVID-19 disease. *Aging* 2021; **13**:1–15.

12. Benetos A, Lai TP, Toupance S, et al. The Nexus Between Telomere Length and Lymphocyte Count in Seniors Hospitalized With COVID-19. *The Journals of Gerontology: Series A*; 2021: glab026

13. Froidure A, Mahieu M, Hoton D, et al. Short telomeres increase the risk of severe COVID-19. *Aging* 2020; **12**: 19911­­–19922.

14. Sudlow C, Gallacher J, Allen N, et al. UK Biobank : An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PloS Med*. 2015; **12:** e1001779.

15. Codd V, Wang Q, Allara E, et al. Polygenic basis and biomedical consequences of telomere length variation. *MedRxiv* 2021; https://doi.org/10.1101/2021.03.18.21253457

16. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 2018; **562**: 203–209.

17. Armstrong J, Rudkin J, Allen N, et al. Dynamic linkage of COVID-19 test results between Public Health England’s Second Generation Surveillance System and UK Biobank. *Microb Genom* 2020; **6**: mgen000397.

18. Cole SR, Platt RW, Schisterman EF, et al. Illustrating bias due to conditioning on a collider. *Int J. Epidemiol*. 2010; **39**: 417–20.

19. Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. *Nature Comms*. 2020; **11**: 5749.

20. Minelli C, Del Greco MF, van der Plaat DA, Bowden J, Sheehan NA, Thompson J. The use of two-sample methods for Mendelian randomization analyses on single large datasets*. Int J Epidemiol.* 2021; **26**:dyab084. Epub ahead of print.

21. Burgess S, Butterworth A, Thompson S.G. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol*. 2013; **37**:658–65.

22. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol*. 2016; **40**: 304–14 (2016).

23. Bowden J, Davey Smith G and Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015; **44**: 512–25.

24. Moro-Garcia MA, Alonso Arias R, Lopez-Larrea C. Molecular mechanisms involved in the aging of the T cell immune response. Curr Genom. 2012; 13: 589–602 (2012).

25. Nehme J, Borghesan M, Mackedenski S, Bird TG, Demaria M. Cellular senescence as a potential mediator of COVID-19 severity in the elderly. *Aging Cell* 2020; **19**: e13237.

26. Bellon M. & Nicot C. Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection*. Viruses.* 2017; **9**: 289.

27. Gadalla SM, et al. Donor telomere length and causes of death after unrelated hematopoietic cell transplantation in patients with marrow failure. *Blood.* 2018; **131**:2393-2398.

28. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. *Lancet* 2003;**361**:393-395.

29. Fry A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. *Am J Epidemiol* 2017; **186**: 1026–1034.

30. Batty GD, Gale CR, Kivimäki, M, Deary IJ, Bell S. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. *BMJ* 2020; 368:m131.

31. The COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur J Hum Genet* 2020; **28**: 715–718.

**Data sharing**

Source data is accessible via application to the UK Biobank.

**Acknowledgements**

This research has been conducted using the UK Biobank Resource under Application Number 6077 and was funded by the UK Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council and British Heart Foundation (BHF) through MRC grant MR/M012816/1. C.P.N is funded by the BHF (SP/16/4/32697). V.C., C.M., V.B., Q.W., C.P.N. and N.J.S. are supported by the National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Centre (BRC-1215-20010). Cambridge University investigators are supported by the B.H.F (RG/13/13/30194; RG/18/13/33946), Health Data Research UK, NIHR Cambridge Biomedical Research Centre (BRC-1215-20014), NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024) and MRC (MR/L003120/1). J.D. holds a BHF Personal Professorship and NIHR Senior Investigator Award. A.M.W. and E.A. received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart (11607). Z.R.E. is supported by BHF Clinical Research Training Fellowship No. FS/17/81/33318. S.E.P. acknowledges support from the NIHR Barts Biomedical Research Centre.

**Author Contributions**

V.C., C.P.N., J.N.D, S.E.P, N.C.H. and N.J.S conceived the project. All authors contributed to the sample definition and the analysis plan. Q.W., C.M. and C.P.N. performed the analyses. V.C., C.P.N., Q.W. and N.J.S. prepared the manuscript and all authors revised it. V.C., C.P.N., J.R.T., J.N.D. and N.J.S. (Principal investigator) secured funding and oversaw the project.

**Competing Interests Declaration**

The authors declare no competing interests.

**Table 1. Characteristics of participants by case status.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Trait** | **Cases N=914** | **Controls N=5861** | **P-value** |
| **Age at COVID-19 test** | 70 (8.00) | 64 (8.00) | 1.85E-95 |
| **BMI** | 29.61 (5.39) | 27.97 (4.86) | 1.55E-20 |
| **Sex** | **Male** | 573 (62.69) | 2675 (45.64) | 8.20E-22 |
| **Female** | 341 (37.31) | 3186 (54.36) |
| **Ethnicity** | **Asian** | 33 (3.61) | 217 (3.70) | 0.006 |
| **Black** | 5 (0.55) | 38 (0.65) |
| **Chinese** | 3 (0.33) | 9 (0.15) |
| **Mixed** | 36 (3.94) | 117 (2.00) |
| **Other** | 8 (0.88) | 78 (1.33) |
| **White** | 829 (90.70) | 5402 (92.17) |
| **Smoking** | **Never** | 358 (39.43) | 3236 (55.38) | 1.27E-18 |
| **Ex-smoker** | 408 (44.93) | 2001 (34.25) |
| **Current** | 142 (15.64) | 606 (10.37) |
| **LTL (age adjusted)** | -0.14 (0.97) | -0.03 (1.00)  | 0.002 |

Data shown are mean (SD) for continuous traits or n (%) for categorical traits. LTL, smoking status, BMI, sex and ethnicity are from baseline information. LTL is log-transformed and Z-standardised. P-values were obtained via t-tests for continuous traits, Ethnicity was assessed using Fishers exact test and other categorical traits were tested using a χ2 test.

**Table 2. Results of the main and secondary/sensitivity analyses.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **N cases** | **N controls** | **Odds Ratio (95%CI)** | **P-value** |
| **Composite outcome** |
| LTL (age-adjusted) (per 1 SD shorter) | 914 | 5861 | 1·17 (1·05 , 1·30) | 0·004 |
| Age at COVID-19 test (per 5 yrs older) | 1·58 (1·51 , 1·65) | <0·001 |
| Sex (male vs female) | 1·88 (1·62 , 2·19) | <0·001 |
| Ethnicity (non-White vs White) | 1·80 (1·39 , 2·34) | <0·001 |
| **Separate components as outcome\*** |
| Hospitalisation | 672 | 5861 | 1·17 (1·03 , 1·32) | 0·013 |
| Critical care support | 383 | 1·31 (1·12 , 1·53) | <0·001 |
| Respiratory support | 279 | 1·36 (1·13 , 1·64) | <0·001 |
| Death | 157 | 1·36 (1·07 , 1·72) | 0·013 |
| **Population controls** |
| LTL (age-adjusted) (per 1 SD shorter) | 914 | 465,946 | 1·19 (1·08 , 1·31) | <0·001 |
| **Excluding participants with recent hospitalisation** |
| LTL (age-adjusted) (per 1 SD shorter) | 732 | 5861 | 1·15 (1·02 , 1·30) | 0·019 |
| **Mendelian Randomisation** |
| MR IVW | 914 | 5861 | 1.30 (0.85 , 2.00) | 0·224 |
| MR-median |  |  | 1.25 (0.62 , 2.50) | 0·537 |

The main analysis is based on our composite outcome and the full multivariable model estimates are shown for each risk factor. \*For each component of the composite outcome analysed separately, the results shown for these are labelled by outcome component but represent the LTL (age-adjusted) estimate (per 1 SD shorter). For each analysis, the numbers of cases and controls are given alongside the odds ratio, 95% confidence interval and P-value (from logistic regression models or MR). MR IVW: Mendelian randomisation inverse-variance weighted method. MR-median: Mendelian randomisation weighted median method.

**Figure 1. Venn diagram showing the distribution of the individual components of the primary outcome.**

 

Where N is the frequency and: Hospitalised, due to COVID-19; Critical care admission, due to COVID-19; Respiratory Support needed, while in critical care due to COVID-19; Death due to COVID-19.